o2h Discovery is pleased to welcome the Milner Therapeutics Institute (MTI) as an official Platinum Partner. The o2h Discovery Platinum Partner Programme enables investors, venture builders, technology transfer offices and innovation ecosystems to extend integrated drug discovery support to the early-stage biotechnology companies they work with.

Through this collaboration, eligible companies within the Milner Bio-incubator and wider MTI innovation ecosystem will gain access to the o2h Kickstarter Award alongside the Institute’s scientific, academic and industry support. By combining complementary expertise in translational science and integrated drug discovery, the partnership aims to help founders accelerate early-stage therapeutic programmes, generate critical scientific data and progress more efficiently towards key technical and investment milestones.

Eligible companies introduced through the programme may benefit from:

• A dedicated team of six synthetic chemists for up to six months to accelerate small molecule discovery programmes.
• High-purity linear, cyclic and constrained peptide synthesis supports to rapidly expand peptide SAR programmes.
• 100 complimentary ADME points and a 20% discount on biology services.
• Integrated project management support delivered through o2h Discovery’s multidisciplinary discovery teams.

The collaboration also builds on an existing relationship between the two organisations. Former Milner Bio-incubator resident TRIMTECH Therapeutics previously received an o2h Kickstarter Award, demonstrating how combining MTI’s innovation ecosystem with o2h Discovery’s integrated drug discovery expertise can help promising biotechnology companies accelerate their therapeutic programmes.

The o2h Kickstarter Award is backed by o2h Discovery’s integrated drug discovery platform and team of more than 800 scientists, providing support across medicinal chemistry, peptide discovery, ADME and biology.

Since its launch, the o2h Kickstarter Award has supported more than 40 biotechnology startups across the UK, USA, Europe, Australia and Israel, helping founders generate critical scientific data, achieve key technical milestones and build stronger foundations for future fundraising and strategic partnerships. 

 

Alexandra Huener, Head of Entrepreneurship, Milner Therapeutics Institute, commented:

We’re delighted to become a Platinum Partner of the o2h Kickstarter Programme. Supporting early-stage life science companies is at the heart of what we do at the Milner Institute’s Bio-incubator, and this partnership will help more founders access the expertise and resources they need to accelerate their science.

We’ve already seen the value of the programme through our former resident company, TRIMTECH Therapeutics, which received an o2h Kickstarter Award and worked with the o2h Discovery team to advance its medicinal chemistry programme and targeted protein degradation platform. We look forward to building on that success and helping the next generation of biotech companies translate promising science into new therapies.

Sunil Shah, Co-founder of o2h Discovery, commented:

The o2h Kickstarter Award was created to help early-stage biotech companies access the scientific expertise and discovery capabilities needed to reach their next milestone. Over the past few years, we’ve had the privilege of supporting more than 40 startups globally, and the Platinum Partner Programme is a natural extension of that journey. We are delighted to welcome Milner Therapeutics Institute as a Platinum Partner and look forward to working together to help more founders accelerate their science and build successful biotechnology companies.

The partnership reflects a shared commitment between Milner Therapeutics Institute and o2h Discovery to strengthen the biotech innovation ecosystem and help promising science progress more efficiently towards meaningful therapeutic impact.

 

---

 

About the Milner Therapeutics Institute

The Milner Therapeutics Institute (MTI) is a purpose-built research institute at the University of Cambridge. The overarching vision of the MTI is to transform pioneering science into therapies. The MTI is breaking new ground in academic–industry collaboration and demonstrates a world-leading model of start-up companies, academics, and pharmaceutical partners working side by side at the bench.

For more information, visit: https://www.milner.cam.ac.uk 

 

About the Milner Bio-incubator

The Milner’s bio-incubator supports innovative early-stage biotechnology companies developing cutting-edge therapies and technologies across oncology, rare diseases, immunotherapy, neuroscience, and longevity and healthy ageing. The institute provides a unique environment at the interface of academia and industry, enabling companies to apply breakthrough science to drug discovery and translational medicine within a highly collaborative ecosystem.

For more information, visit: https://www.milner.cam.ac.uk/incubator 

 

About o2h Discovery

Founded in 2005, o2h Discovery operates an integrated drug discovery platform across Cambridge, UK and Ahmedabad, India. With expertise spanning medicinal chemistry, biology, DMPK, peptide discovery, scale-up chemistry and project management, o2h Discovery supports biotechnology and pharmaceutical companies from hit identification through lead optimisation and into IND-enabling studies.

For more information, visit www.o2hdiscovery.co

 

About the o2h Kickstarter Award

Launched in 2022, the o2h Kickstarter Award was created to provide a chemistry and discovery boost to early-stage biotech companies developing novel therapeutics. The programme supports companies that have secured initial funding and are seeking to generate critical scientific data ahead of their next funding milestone.

Since launch, the programme has completed multiple international editions across the UK, USA, Europe, Australia and Israel, supporting more than 40 biotechnology companies globally. Award recipients receive access to dedicated chemistry teams, integrated discovery expertise and project management support designed to accelerate early-stage drug discovery programmes.

For more information, visit https://o2h.com/the-o2h-kickstarter-competition/ 

 

About the o2h Discovery Platinum Partner Programme

The o2h Discovery Platinum Partner Programme enables venture capital firms, venture builders, incubators, accelerators, technology transfer offices and innovation ecosystems to extend the benefits of the o2h Kickstarter Award directly to eligible portfolio companies and ventures. By combining investment, strategic guidance and integrated drug discovery support, the programme helps early-stage biotechnology companies generate the scientific data needed to achieve critical technical, commercial and fundraising milestones.

Through this collaborative model, Platinum Partners can offer their founders access to medicinal chemistry, peptide discovery, biology, ADME and project management expertise at a stage where scientific progress is often constrained by limited resources. The programme reflects o2h Discovery’s commitment to strengthening the global biotech innovation ecosystem by helping more promising therapies progress from early discovery towards meaningful clinical and commercial outcomes.

For more information, visit: https://o2h.com/o2h-discovery-platinum-partner/